Wikipedia:Version 1.0 Editorial Team/Pharmacology articles by quality log
 | This is a log of operations by a bot. The contents of this page are unlikely to need human editing. In particular, links should not be disambiguated as this is a historical record. |
July 3, 2024[edit]
Reassessed[edit]
- Donanemab (talk) reassessed. Importance rating changed from Low-Class to Mid-Class. (rev · t)
- Gonadotropin-releasing hormone (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)
Assessed[edit]
- Draft:Eunice Ego Mgbeahuruike (talk) assessed. Importance assessed as NA-Class. (rev · t)
July 2, 2024[edit]
Assessed[edit]
- Draft:LAPaL (talk) assessed. Importance assessed as NA-Class. (rev · t)
July 1, 2024[edit]
Reassessed[edit]
- Androgen (medication) (talk) reassessed. Quality rating changed from Unassessed-Class to List-Class. (rev · t)
- Bex (compound analgesic) (talk) reassessed. Quality rating changed from Unassessed-Class to C-Class. (rev · t)
- Compound management (talk) reassessed. Quality rating changed from Unassessed-Class to Start-Class. (rev · t)
- Levomoramide (talk) reassessed. Quality rating changed from Unassessed-Class to Stub-Class. (rev · t)
- Molecule-based magnets (talk) reassessed. Quality rating changed from Unassessed-Class to C-Class. (rev · t)
- Nanocell (talk) reassessed. Quality rating changed from Unassessed-Class to Start-Class. (rev · t)
- Polymer-drug conjugates (talk) reassessed. Quality rating changed from Unassessed-Class to Start-Class. (rev · t)
- Protide (talk) reassessed. Quality rating changed from Unassessed-Class to C-Class. (rev · t)
- Seidlitz powders (talk) reassessed. Quality rating changed from Unassessed-Class to C-Class. (rev · t)
Assessed[edit]
- Luozi Pharmaceutical Research Center (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
June 30, 2024[edit]
Renamed[edit]
Reassessed[edit]
- Evolocumab (talk) reassessed. Importance rating changed from Low-Class to Mid-Class. (rev · t)
Assessed[edit]
- Gamithromycin (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)
- Life sciences industry in Switzerland (talk) assessed. Quality assessed as C-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
- Maropitant (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)
- Scioderm (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
- Selamectin (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)
June 29, 2024[edit]
Reassessed[edit]
- Osaterone acetate (talk) reassessed. Importance rating changed from Low-Class to Mid-Class. (rev · t)
Assessed[edit]
- Compound management (talk) assessed. Quality assessed as Unassessed-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
- IHCH-7079 (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
- IHCH-7086 (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
June 28, 2024[edit]
Renamed[edit]
- RPL-554 renamed to Ensifentrine.
Reassessed[edit]
- Equianalgesic/Archive 1 (talk) reassessed. Quality rating changed from List-Class to NA-Class. (rev · t) Importance rating changed from Unknown-Class to NA-Class. (rev · t)
Assessed[edit]
- Ensifentrine (talk) assessed. Quality assessed as NA-Class. (rev · t) Importance assessed as NA-Class. (rev · t)
- Protide (talk) assessed. Quality assessed as Unassessed-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
June 27, 2024[edit]
Reassessed[edit]
- Ahmed Hegazy (pharmacist) (talk) reassessed. Quality rating changed from C-Class to Start-Class. (rev · t)